Bristol Myers Squibb (CELG-RI) Intangibles (2009 - 2026)

Bristol Myers Squibb (CELG-RI) posted quarterly Intangibles of $18.2 billion for Q1 2026, down 18.87% YoY from $22.5 billion in Q1 2025, and down 4.5% sequentially from $19.1 billion in Q4 2025.

Bristol Myers Squibb (CELG-RI) Intangibles (2009 - 2026) Analysis & Trends

Bristol Myers Squibb has disclosed Intangibles across 18 years of filings, most recently posting $18.2 billion for Q1 2026.

  • In Q1 2026, Intangibles fell 18.87% year-over-year to $18.2 billion; the TTM figure through Mar 2026 stood at $18.2 billion (down 18.87% YoY), while the FY2025 annual figure was $19.1 billion, down 18.04% from the prior year.
  • Intangibles retreated to $18.2 billion in Q1 2026, from $19.1 billion in the prior quarter.
  • Over the last five years, Intangibles for CELG-RI reached as high as $40.1 billion in Q1 2022 and fell as low as $18.2 billion in Q1 2026.
  • The 5-year median for Intangibles is $29.0 billion (2023), against an average of $28.6 billion.
  • Annual changes were most pronounced in 2024 — Intangibles retreated 2.41% — and 2025, when it slumped 31.36%.
  • A 5-year view of Intangibles shows it stood at $35.9 billion in 2022, then retreated by 24.5% to $27.1 billion in 2023, then dropped by 13.91% to $23.3 billion in 2024, then dropped by 18.04% to $19.1 billion in 2025, then declined by 4.5% to $18.2 billion in 2026.
  • According to Business Quant data, Intangibles over the past three periods registered $18.2 billion, $19.1 billion, and $20.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Intangibles (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn 7.37 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn 49.06 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 50.87 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 36.91 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn 25.75 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn 21.38 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 16.38 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 52.56 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn - 11.30 Bn
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn 18.24 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 18.24 Bn
Dec 31, 2025 19.10 Bn
Sep 30, 2025 20.47 Bn
Jun 30, 2025 21.38 Bn
Mar 31, 2025 22.49 Bn
Dec 31, 2024 23.31 Bn
Sep 30, 2024 26.96 Bn
Jun 30, 2024 29.43 Bn
Mar 31, 2024 32.76 Bn
Dec 31, 2023 27.07 Bn
Sep 30, 2023 28.95 Bn
Jun 30, 2023 31.30 Bn
Mar 31, 2023 33.57 Bn
Dec 31, 2022 35.86 Bn
Sep 30, 2022 38.18 Bn
Jun 30, 2022 37.69 Bn
Mar 31, 2022 40.10 Bn
Dec 31, 2021 42.53 Bn
Sep 30, 2021 44.93 Bn
Jun 30, 2021 48.07 Bn